Point Thera raises nearly $5M in stock sale

12 February 2007

Boston,USA-based Point Therapeutics says that it has priced a registered direct offering for the sale of 6,523,776 shares of its common stock at a price of $0.73 per share. The investors in this will also receive five-year warrants, exercisable upon expiration of a lock-up period of six-months, to buy an additional 978,566 shares at an exercise price of $1.00 each.

The company expects the transaction, which will gross some $4.76 million, to close on February 6, subject to the satisfaction of customary closing conditions. The offered shares are registered pursuant to Point's shelf registration statement that was declared effective by the Securities and Exchange Commission on January 12, 2005.

The net proceeds are intended to fund the further clinical development of talabostat and general corporate purposes, including R&D and general and administrative expenses.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight